We have a great pleasure to announce that Genomtec’s diagnostic pipeline has received Horizon 2020 SME phase I grant. In particular Experts of European Commission awarded Genomtec Tumor solution for cancer diagnosis. The grant will enable Genomtec to tailor the offering for the market needs as well as prepare the solution for further development.
Genomtec Tumor is a POCT device working on the patent-pending SNAAT technology of photon-based contactless heating and created in house diagnostic assays. It will enable rapid cancer diagnosis based on amplification of specific fragments of nucleic acids. Furthermore, it can aid in introduction of personalized therapy once the cancer has been diagnosed.